Please login to the form below

Not currently logged in
Email:
Password:

cHL

This page shows the latest cHL news and features for those working in and with pharma, biotech and healthcare.

Latest news

  • China’s BeiGene takes PD-1 antibody into pivotal trials China’s BeiGene takes PD-1 antibody into pivotal trials

    The single-arm trial enrolled 70 cHL patients who had failed autologous stem cell transplantation (ASCT) – a primary treatment for the cancer – or were ineligible for the procedure.

  • Merck suspends two Keytruda trials after patient deaths Merck suspends two Keytruda trials after patient deaths

    Earlier this year Keytruda was approved for classical Hodgkin lymphoma (cHL) - its first non-solid tumour indication - and expanding into blood cancers is a key target for Merck.

  • Keytruda and Opdivo backed for new uses in Europe Keytruda and Opdivo backed for new uses in Europe

    cHL), shortly after the FDA cleared the drug for the same blood cancer in the US. ... BMS' Opdivo (nivolumab) - which is already approved in the EU for cHL - was given the nod for the treatment for adults with squamous cell cancer of the head and neck

  • Keytruda claims first blood cancer OK from FDA Keytruda claims first blood cancer OK from FDA

    Merck &Co wins US approval for its haematological cancer treatment. Merck &Co has won FDA clearance for its PD-1 inhibitor Keytruda in classical Hodgkin lymphoma (cHL), the first green light ... The US regulator gave a conditional approval to Keytruda

  • Opdivo gets green light for Hodgkin lymphoma in Europe Opdivo gets green light for Hodgkin lymphoma in Europe

    Less common than non-Hodgkin's lymphoma, cHL affects around 12, 200 people in the EU every year, often being diagnosed in early adulthood. ... BMS says the drug is still showing robust growth in other indications such as melanoma, renal cancer and cHL.

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    CDA). The company is filing first for patients with relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) – a niche indication not yet taken in China by Keytruda and Opdivo, which

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics